DRKS00000403
Not yet recruiting
Phase 4
Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control - OXT_fMRT
Rheinisch-Westfälische Technische Hochschule Aachenvertretn durch das CTC-A derMedizinischen Fakultät der RWTH Aachen0 sites96 target enrollmentMay 10, 2010
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- F40.1
- Sponsor
- Rheinisch-Westfälische Technische Hochschule Aachenvertretn durch das CTC-A derMedizinischen Fakultät der RWTH Aachen
- Enrollment
- 96
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •inclusion criteria for control group:
- •Age between 18 and 45,
- •Full capacity to understand and execute instructions of the study,
- •signed form of consent.
- •inclusion criteria for patient group:
- •Age between 18 and 45,
- •diagnosis of social phobia (according to ICD\-10\),
- •The screening methods applied are the Social Phobia Inventory (SPIN, patient assessment) using a minimal score of 19 and the Liebowitz Anxiety Scale (LAS, assessment by interviewer, minimal score of 55 points),
- •Full capacity to understand and execute instructions of the study,
- •signed form of consent.
Exclusion Criteria
- •Sinistrality
- •Neurological or Somatic illness affecting the cerebral function (e.g. Parkinsons Disease, Epilepsy, Multiple Sclerosis, Brain Tumor)
- •Psychiatric disorder according to ICD\-10\-WHO F0\-F3, F8
- •Psychiatric disorder according to ICD\-10\-WHO F (applicable in patients only in untreated or if acute occurrence in the last six months)
- •Incorporated metal
- •Positive drug test and accordingly supposed or actual alcohol or drug abuse
- •Consumption of centrally acting substances (Except therapeutic in patients)
- •Persons committed governmental or legally to an institution
- •Any other medical condition or treatment that could interfere with the security, tolerance or efficacy in appraisal of the investigators
- •Participation in other or interfering clinical studies concurrently or in the last 90 days or 5 half\-lives of the medical substance, respectively (whichever is longer), before screening
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control - OXT_fMRTThe effect of oxytocin is investigated in social processing of social phobic patient and healthy controlsMedDRA version: 12.0Level: LLTClassification code 10041250Term: Social phobiaEUCTR2009-015538-30-DERheinisch-Westfälisch Technische Hochschule Aachen
Completed
Early Phase 1
Methadone Oxytocin OptionSubstance AbuseOpioid DependenceMethadone TreatmentNCT01728909University of California, San Francisco64
Completed
Phase 2
Oxytocin Administration in BDD and OCDBody Dysmorphic DisorderObsessive-compulsive DisorderNCT02671266Massachusetts General Hospital41
Completed
Phase 1
Oxytocin Treatment of Social Cognitive and Functional Deficits in SchizophreniaSchizophreniaSchizoaffective DisorderNCT01394471University of North Carolina, Chapel Hill68
Completed
Not Applicable
The Influence of Intranasal Oxytocin on CommunicationHealthyNCT02415920University of British Columbia50